CervoMed's Neflamapimod Awarded UK Innovation Passport for DLB Treatments
CervoMed Inc. received an Innovation Passport for neflamapimod under the UK's ILAP program to accelerate its development for Lewy body dementia. Regulatory approval marks a significant step toward addressing this unmet medical need.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day